Last Updated: 2026-03-24 PT
Sleep and circadian rhythm disturbances are increasingly recognized as both early biomarkers and modifiable risk factors in neurodegenerative diseases. This knowledge gap page catalogs critical unanswered questions about the bidirectional relationship between sleep/circadian dysfunction and neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), and related disorders.[1][2][3]
| Dimension | Score | Rationale |
|---|---|---|
| Impact if Solved | 8/10 | Sleep interventions could improve quality of life and potentially modify disease progression |
| Tractability | 7/10 | Wearable devices and CSF biomarkers enable measurement; intervention feasibility exists |
| Under-exploration | 9/10 | Significant gap between prevalence of sleep complaints and research investment |
| Data Availability | 7/10 | Emerging cohorts with sleep data; need for standardized protocols |
| Total | 31/40 | Tier 1 - Highest-priority strategic gap |
Question: Can polysomnographic or wearable-derived sleep metrics predict conversion from preclinical to clinical neurodegeneration?
Current State:
Research Priorities:
Cross-links: Sleep and Neurodegeneration, Biomarkers for Alzheimer's
Question: What determines whether idiopathic RBD converts to PD, Dementia with Lewy Bodies (DLB), or remains isolated?
Current State:
Research Priorities:
Cross-links: Alpha-Synuclein Prion-Like Spreading, Parkinson's Disease Knowledge Gaps
Question: Does circadian disruption accelerate neurodegeneration, or is it merely a downstream effect?
Current State:
Research Priorities:
Cross-links: Circadian Disruption in Neurodegeneration, Tau Causality vs Bystander
Question: Do sleep-targeted interventions (pharmacological, behavioral, device-based) modify neurodegenerative disease progression?
Current State:
Research Priorities:
Cross-links: GLP-1 Receptor Agonist Responder Biology, Subtype-Specific Target Engagement
Question: What is the role of sleep disruption in tauopathies and TDP-43 proteinopathies?
Current State:
Research Priorities:
Cross-links: ALS Knowledge Gaps, Tau vs TDP-43 Fate Switching, FTD Knowledge Gaps
| Disease | Top Sleep/Circadian Gap | Score |
|---|---|---|
| Alzheimer's disease | Sleep as early biomarker; glymphatic clearance modulation | 31 |
| Parkinson's disease | RBD phenotype prediction; circadian-based interventions | 32 |
| ALS | Sleep disruption mechanisms; TDP-43 relationship | 28 |
| FTD | Circadian behavioral disturbances; therapeutic response | 27 |
Ju YE et al. Sleep and neurodegeneration. J Clin Sleep Med. 2014. ↩︎
Videnovic A & Willis GL. Circadian function in neurodegenerative diseases. Lancet Neurol. 2016. ↩︎
Zaltieri M et al. Sleep disturbances in neurodegenerative diseases. Cell Mol Life Sci. 2022. ↩︎
Iranzo A et al. Long-term follow-up of isolated REM sleep behavior disorder. Neurology. 2016. ↩︎
Hogl B et al. Sleep and neurodegeneration. Lancet Neurol. 2020. ↩︎
Schenck CH et al. REM sleep behavior disorder. Sleep Med Clin. 2013. ↩︎
Gan-Or Z et al. GBA mutations are associated with rapid eye movement sleep behavior disorder. Ann Neurol. 2015. ↩︎
Swaab DF et al. Circadian rhythm of suprachiasmatic nucleus in Alzheimer's disease. Prog Brain Res. 2014. ↩︎
Gu Z et al. Association between PER3 polymorphisms and Parkinson's disease. Front Neurol. 2018. ↩︎
Chen H et al. Shift work and Parkinson's disease. Environ Health Perspect. 2010. ↩︎
Nedergaard M et al. Sleep drives metabolite clearance from the adult brain. Science. 2013. ↩︎
Liguori C et al. Obstructive sleep apnea and Alzheimer's disease. Neurol Sci. 2020. ↩︎
Zhang W et al. Melatonin for neurodegenerative diseases. Neurobiol Dis. 2022. ↩︎
Raemdonck K et al. Sleep disturbances in amyotrophic lateral sclerosis. J Neurol Sci. 2014. ↩︎